[go: up one dir, main page]

WO2009107971A3 - 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도 - Google Patents

포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도 Download PDF

Info

Publication number
WO2009107971A3
WO2009107971A3 PCT/KR2009/000882 KR2009000882W WO2009107971A3 WO 2009107971 A3 WO2009107971 A3 WO 2009107971A3 KR 2009000882 W KR2009000882 W KR 2009000882W WO 2009107971 A3 WO2009107971 A3 WO 2009107971A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphatidylserine
polypeptide
specifically coupled
present
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/000882
Other languages
English (en)
French (fr)
Other versions
WO2009107971A2 (ko
Inventor
김인산
이병헌
나렌드라타빠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Priority to CN200980106312.8A priority Critical patent/CN101965356B/zh
Priority to EP09714117.0A priority patent/EP2280024B1/en
Priority to JP2010547569A priority patent/JP5055438B2/ja
Publication of WO2009107971A2 publication Critical patent/WO2009107971A2/ko
Publication of WO2009107971A3 publication Critical patent/WO2009107971A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도에 관한 것으로서, 보다 상세하게는 서열번호 1로 표시되는 아미노산 서열을 가지며, 포스파티딜세린과 특이적으로 결합하는 폴리펩티드, 이의 포스파티딜세린 검출용도, 이를 이용하는 포스파티딜세린 검출방법, 이의 사멸세포 검출용도, 이의 약물 전달용도, 이의 종양성 질환 치료용도, 종양성 질환부위의 영상화용도 등에 관한 것이다. 본 발명의 서열번호 1로 표시되는 아미노산 서열을 가지는 폴리펩티드는 포스파티딜세린과 특이적으로 결합할 수 있다. 따라서, 본 발명의 폴리펩티드는 포스파티딜세린의 검출, 더 나아가 포스파티딜세린을 세포 표면으로 발현하는 사멸세포 및 종양세포의 검출 또는 영상화 등에 다양하게 사용될 수 있다.
PCT/KR2009/000882 2008-02-25 2009-02-25 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도 Ceased WO2009107971A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN200980106312.8A CN101965356B (zh) 2008-02-25 2009-02-25 以特异方式与磷脂酰丝氨酸结合的多肽及其用途
EP09714117.0A EP2280024B1 (en) 2008-02-25 2009-02-25 Polypeptide specifically binding to phosphatidylserine and use thereof
JP2010547569A JP5055438B2 (ja) 2008-02-25 2009-02-25 ホスファチジルセリンと特異的に結合するポリペプチド及びこれの用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0016944 2008-02-25
KR1020080016944A KR100968839B1 (ko) 2008-02-25 2008-02-25 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도

Publications (2)

Publication Number Publication Date
WO2009107971A2 WO2009107971A2 (ko) 2009-09-03
WO2009107971A3 true WO2009107971A3 (ko) 2009-11-26

Family

ID=40998508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000882 Ceased WO2009107971A2 (ko) 2008-02-25 2009-02-25 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도

Country Status (6)

Country Link
US (1) US8133971B2 (ko)
EP (1) EP2280024B1 (ko)
JP (1) JP5055438B2 (ko)
KR (1) KR100968839B1 (ko)
CN (1) CN101965356B (ko)
WO (1) WO2009107971A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2437773T3 (en) * 2009-06-03 2017-02-06 Mosamedix Bv PROCEDURE FOR IMPROVING PHAGOCYTOSIS OF PHOSPHATIDYLSERINE-EXPOSING CELLS
FI3524617T3 (fi) 2013-03-15 2023-06-26 Gladiator Biosciences Inc Gla-domeenit terapeuttisina aineina
US9388193B2 (en) * 2014-05-22 2016-07-12 National Health Research Institutes Dipicolylamine derivatives and their pharmaceutical uses
KR101802302B1 (ko) 2015-01-21 2017-11-28 가천대학교 산학협력단 포스파티딜이노시톨포스페이트 결합 물질의 세포 사멸 검출 용도
JP2020533404A (ja) 2017-09-05 2020-11-19 グラディエーター バイオサイエンシーズ インコーポレイテッド 細胞内送達法
CN115364111B (zh) * 2021-05-17 2024-04-02 中国医学科学院基础医学研究所 甘油磷脂类化合物在治疗肿瘤中的用途
CN115718129B (zh) * 2021-08-24 2025-09-02 中国科学院烟台海岸带研究所 一种以多肽为识别分子检测凋亡细菌的方法及装置
WO2025154104A1 (en) * 2024-01-20 2025-07-24 Ur Advanced Therapeutics Private Limited Non-cell penetrating, metacyclic synthetic peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138419A1 (en) * 2001-11-16 2003-07-24 The University Of Tennessee Research Corporation Recombinant antibody fusion proteins and methods for detection of apoptotic cells
US6949350B1 (en) * 1999-03-12 2005-09-27 Evotec Analytical Systems Gmbh Chemosensitivity determination using phosphatidylserine
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726895B2 (en) * 2001-04-03 2004-04-27 Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949350B1 (en) * 1999-03-12 2005-09-27 Evotec Analytical Systems Gmbh Chemosensitivity determination using phosphatidylserine
US20030138419A1 (en) * 2001-11-16 2003-07-24 The University Of Tennessee Research Corporation Recombinant antibody fusion proteins and methods for detection of apoptotic cells
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CATHERINE LAUMONIER ET AL.: "A new peptidic vector for molecular imaging of apoptosis, identified by phage display technology.", JOURNAL OF BIOMOLECULAR SCREENING., vol. 11, no. 5, 2006, pages 537 - 545 *
See also references of EP2280024A4 *

Also Published As

Publication number Publication date
KR20090091589A (ko) 2009-08-28
US8133971B2 (en) 2012-03-13
US20090214430A1 (en) 2009-08-27
CN101965356B (zh) 2014-03-26
EP2280024A4 (en) 2011-03-30
KR100968839B1 (ko) 2010-07-09
EP2280024B1 (en) 2014-12-17
CN101965356A (zh) 2011-02-02
JP2011515075A (ja) 2011-05-19
EP2280024A2 (en) 2011-02-02
JP5055438B2 (ja) 2012-10-24
WO2009107971A2 (ko) 2009-09-03

Similar Documents

Publication Publication Date Title
WO2009107971A3 (ko) 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도
WO2007112757A3 (en) A process for concentration of a polypeptide
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
EP4223783A3 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
JP2007508034A5 (ko)
EP2455462A3 (en) Lipase variants for pharmaceutical use
NZ596037A (en) Fgf21 mutants and uses thereof
WO2009083225A3 (en) Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
TW200716589A (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
WO2004062602A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
WO2011029008A3 (en) Synbodies to akt1
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
WO2012124998A3 (ko) 바이오핀
WO2013040478A3 (en) Hyr1-derived compositions and methods of treatment using same
MX2010005816A (es) Epítopos de péptido de stat3.
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
WO2011060613A9 (zh) 人α-防御素5突变体多肽及其制备方法和应用
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells
WO2010077364A3 (en) Stroke-generated angiogenesis enhancers and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980106312.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09714117

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010547569

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5869/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009714117

Country of ref document: EP